Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05224102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

Study acronym: ELEVATUM
StatusActive, Not Recruiting
PhasePhase 4
Started2022-02-28
View on ClinicalTrials.gov ↗
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.

Amendment record

Amended 48 times since 2022-01-25; most recent filed 2026-08-24. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.

2026-08-24
Amendment Study Status v48
2026-05-26
Amendment Study Status, Contacts/Locations v47
2026-02-26
Amendment Study Status v46
2025-11-28
Amendment Study Status v45
2025-09-01
Amendment Study Status v44
2025-06-03
Amendment Study Status v43
2025-03-05
Amendment Recruiting→Active, Not Recruiting Study Status, Contacts/Locations, IPDSharing v42
2025-02-14
Amendment Study Status, Contacts/Locations v41
2025-01-16
Amendment Study Status, Contacts/Locations v40
2024-12-19
Amendment Study Status v39
2024-11-19
Amendment Study Status v38
2024-10-21
Amendment Study Status, IPDSharing v37
2024-09-18
Amendment Study Status, Contacts/Locations v36
2024-08-19
Amendment Study Status v35
2024-07-22
Amendment Study Status v34
2024-06-28
Amendment Study Status, Contacts/Locations v33
2024-06-03
Amendment Study Status, Contacts/Locations v32
2024-05-06
Amendment Study Status v31
2024-04-08
Amendment Study Status v30
2024-03-12
Amendment Study Status, Contacts/Locations v29
2024-02-13
Amendment Study Status, Contacts/Locations v28
2024-01-17
Amendment Study Status, Contacts/Locations v27
2023-12-20
Amendment Study Status v26
2023-11-29
Amendment Study Status, Contacts/Locations v25
2023-11-01
Amendment Study Status v24
2023-10-03
Amendment Study Status, Contacts/Locations v23
2023-09-04
Amendment Study Status v22
2023-08-09
Amendment Study Status, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations, IPDSharing v21
2023-06-27
Amendment Study Status, Contacts/Locations v20
2023-06-07
Amendment Study Status, Contacts/Locations, IPDSharing v19
2023-05-08
Amendment Study Status, Contacts/Locations v18
2023-04-10
Amendment Study Status v17
2023-03-10
Amendment Study Status, Study Description, Study Design, Eligibility, Contacts/Locations v16
2023-03-01
Amendment Study Status, Contacts/Locations v15
2023-01-31
Amendment Study Status v14
2023-01-02
Amendment Study Status, Contacts/Locations v13
2022-12-06
Amendment Study Status, Contacts/Locations v12
2022-11-10
Amendment Study Status, Contacts/Locations v11
2022-10-14
Amendment Study Status v10
2022-09-16
Amendment Study Status v9
2022-08-19
Amendment Study Status, Contacts/Locations v8
2022-07-22
Amendment Study Status, Contacts/Locations v7
2022-06-24
Amendment Study Status, Contacts/Locations v6
2022-05-27
Amendment Study Status, Contacts/Locations v5
2022-04-29
Amendment Study Status, Contacts/Locations v4
2022-04-01
Amendment Study Status, Contacts/Locations v3
2022-03-04
Amendment Study Status, Contacts/Locations v2
2022-02-08
Amendment Not Yet Recruiting→Recruiting Study Identification, Study Status, Arms and Interventions, Contacts/Locations v1
2022-01-25
Original filing
Trial Details
NCT Number NCT05224102
Lead Sponsor Genentech, Inc.
Conditions Diabetic Macular Edema
Enrollment 218 participants
Start Date 2022-02-28
Primary Completion 2027-01-26 (estimated)
Study Completion 2027-01-26 (estimated)
Updated on ClinicalTrials.gov 2026-08-25